Is the price of lorlatinib affordable when included in medical insurance?

Lorlatinib (Lorlatinib), this highly anticipated third-generation tyrosine kinase inhibitor (TKI), is known for its excellent efficacy in ALK (anaplastic lymphoma kinase) and ROS1(C-rosProto-oncogene1) has emerged in the treatment of positive non-small cell lung cancer (NSCLC). It can not only effectively deal with the drug resistance problem after treatment with previous generation TKIs, but also uses its strong blood-brain barrier penetration to accurately attack brain metastases, significantly prolonging the survival of patients, and has become a bright star in the field of advanced lung cancer treatment.

Now, lorlatinib has been approved for marketing in the Chinese market and has been successfully included in the national medical insurance directory. This move has undoubtedly brought great benefits to patients. The implementation of the medical insurance policy has caused the originally high drug prices to drop significantly, reducing the financial burden on patients. At present, after medical insurance reimbursement, the average monthly out-of-pocket expense of patients has dropped to about 10,000 to 20,000 yuan. The specific amount varies depending on regional policies and reimbursement ratios. In order to obtain the most accurate reimbursement information, it is recommended that patients promptly consult the local medical insurance department or hospital pharmacy to ensure the smooth progress of the treatment plan.

However, in the international market, the price of lorlatinib shows a completely different trend. Taking Turkey as an example, the price of original drugs is relatively affordable, with a monthly cost of about 7,000 yuan. In Hong Kong, China, the price of original drugs is as high as 30,000 yuan, prohibiting many patients. Against this background, generic drugs produced in countries such as Laos and Bangladesh have attracted much attention due to their low prices, which usually range from more than 1,000 yuan to several thousand yuan. Although these generic drugs are similar in composition to the brand-name drugs, there may be differences in production quality and stability. Therefore, patients need to choose carefully when purchasing and ensure that they obtain high-quality drugs through formal channels.

The medical insurance coverage of lorlatinib has undoubtedly improved the accessibility of the drug and opened a new door to treatment for ALK or ROS1 positive patients. However, patients still need to strictly follow the doctor's instructions during medication and develop a personalized treatment plan based on individual conditions. At the same time, we should choose compliant and high-quality drug sources based on our own economic conditions to ensure treatment effectiveness and safety. The launch of lorlatinib and the support of medical insurance policies not only mark another major progress in targeted therapy, but also bring unprecedented hope and longer survival to patients with advanced lung cancer.

xa0

References:

China National Medical Products Administration: https://www.nmpa.gov.cn/